title: Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine.
abstract: Anidulafungin is a novel antifungal agent of the echinocandin class that is intended for the treatment of invasive fungal disease. It is likely that anidulafungin will be coadministered with cyclosporine. In vitro studies and clinical studies were performed to evaluate the effect of anidulafungin on cyclosporine metabolism and to investigate the safety and pharmacokinetics of anidulafungin when concomitantly administered with cyclosporine. The potential for anidulafungin to inhibit the metabolism of cyclosporine was evaluated by pooled human hepatic microsomal protein fractions in vitro, incubating 3H-cyclosporine with different concentrations of anidulafungin. The safety of coadministration and the effects of cyclosporine on the pharmacokinetics of anidulafungin were assessed in a multiple-dose, open-label clinical study of 12 healthy volunteers. Subjects received a 200-mg intravenous loading dose of anidulafungin, followed by a daily 100-mg intravenous maintenance dose on days 2 through 8. An oral solution of cyclosporine (Neoral oral solution; 100 mg/mL) 1.25 mg/kg was also administered to subjects twice daily on days 5 through 8. In the in vitro study, the addition of anidulafungin had no effect on cyclosporine metabolism by human hepatic microsomal protein fractions. In the clinical study, no dose-limiting toxicities or serious adverse events occurred. A small increase in anidulafungin concentrations and drug exposure (22%) was observed after 4 days of dosing with cyclosporine and was not considered to be clinically relevant. The results support the concomitant use of anidulafungin and cyclosporine without the need for dosage adjustments of either drug.
authors.affiliation: Pharmacokinetics and Pharmacology, Vicuron Pharmaceuticals, 455 South Gulph Road Suite 310, King of Prussia, PA 19406, USA.
authors.forename: James A
authors.initials: JA
authors.lastname: Dowell
authors.forename: Martin
authors.initials: M
authors.lastname: Stogniew
authors.forename: David
authors.initials: D
authors.lastname: Krause
authors.forename: Timothy
authors.initials: T
authors.lastname: Henkel
authors.forename: Irving E
authors.initials: IE
authors.lastname: Weston
mesh_terms: D000284:Administration, Oral; D000077612:Anidulafungin; D000935:Antifungal Agents / Q000097:blood / Q000737:chemistry / Q000494:pharmacology; D019540:Area Under Curve; D001682:Biological Availability; D016572:Cyclosporine / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D054714:Echinocandins; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008657:Metabolic Clearance Rate; D008826:Microbial Sensitivity Tests / Q000379:methods; D008862:Microsomes, Liver / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D010456:Peptides, Cyclic / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D013997:Time Factors; D014316:Tritium
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D010456:Peptides, Cyclic; D014316:Tritium; D016572:Cyclosporine; D000077612:Anidulafungin